



Covid 19 Vaccines- Pharma Challenges, Technology, Players & Status.



Presenter: Vijai Kumar

AAiPS Web Meeting, August 27th, 7 PM EST.

Join Zoom Meeting

<https://us02web.zoom.us/j/86315437903?pwd=bVVVzekhOd3JNMnpyUHFEbUVyUDFJUT09>

Meeting ID: 863 1543 7903

Passcode: 829096

One tap mobile

+16465588656,,86315437903#,,,,,0#,,829096# US (New York)

+13017158592,,86315437903#,,,,,0#,,829096# US (Germantown)

Dial by your location

+1 646 558 8656 US (New York)

+1 301 715 8592 US (Germantown)

+1 312 626 6799 US (Chicago)

+1 669 900 9128 US (San Jose)

+1 253 215 8782 US (Tacoma)

+1 346 248 7799 US (Houston)

Meeting ID: 863 1543 7903

Passcode: 829096

Find your local number: <https://us02web.zoom.us/u/kiujbyAjA>

Abstract

Never before has the entire pharmaceutical industry focused so quickly and collaboratively on one virus and one disease. As you know the return to normalcy hinges on vaccines — and, more specifically, pharma's ability to meet an extraordinary timeline. The industry is being asked to develop, test, scale-up, manufacture and distribute billions of vaccine doses — in a matter of months. This presentation will discuss the challenges, technology, players and current status to-date. Can pharma industry safely fast-track a process that can normally take a decade? For vaccines, and drugs in general, the road from research to commercialization is often mired with complications, setbacks and unknowns. Does the global industry have the manufacturing capacity to hit the billion dose mark?

About the speaker:

Vijai Kumar is a Senior Associate in the Compliance Practice at Lachman Consultants who assists clients with Quality Assurance and Regulatory compliance. He provides leadership and subject matter expertise, develops manufacturing strategies; resolves complex development, manufacturing and compliance issues. He has extensive experience in the development and manufacture of solid oral dosage forms, liquids, topicals, and small volume parenterals, including high-potency compounds. In addition, he has experience in biopharmaceuticals and biologics. He is the holder of nine patents and the author of a number of scientific peer-reviewed publications, author of a Chapter on Validation of Aseptic Processes in "Aseptic Pharmaceutical Manufacturing II" and on Dissolution in "Remington's The Science and Practice of Pharmacy" 21st. & 22nd. edition.

Currently, President Operations, RK Pharma Inc, Pearl River, New York and he also serves as an active Adjunct Professor at Long Island University-